233 related articles for article (PubMed ID: 16963407)
1. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS).
Qureshi MM; Hayden D; Urbinelli L; Ferrante K; Newhall K; Myers D; Hilgenberg S; Smart R; Brown RH; Cudkowicz ME
Amyotroph Lateral Scler; 2006 Sep; 7(3):173-82. PubMed ID: 16963407
[TBL] [Abstract][Full Text] [Related]
2. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
[TBL] [Abstract][Full Text] [Related]
3. Effects of early introduction of non-invasive positive pressure ventilation based on forced vital capacity rate of change: Variation across amyotrophic lateral sclerosis clinical phenotypes.
Elamin EM; Wilson CS; Sriaroon C; Crudup B; Pothen S; Kang YC; White KT; Anderson WM
Int J Clin Pract; 2019 Jan; 73(1):e13257. PubMed ID: 30230161
[TBL] [Abstract][Full Text] [Related]
4. Demographic characteristics and prognosis in a Flemish amyotrophic lateral sclerosis population.
Thijs V; Peeters E; Theys P; Matthijs G; Robberecht W
Acta Neurol Belg; 2000 Jun; 100(2):84-90. PubMed ID: 10934559
[TBL] [Abstract][Full Text] [Related]
5. [The changes of clinical characteristics in 100 Japanese amyotrophic lateral sclerosis patients between 1980 and 2000].
Kimura F; Shinoda K; Fujiwara S; Fujimura C; Nakajima H; Furutama D; Sugino M; Hanafusa T
Rinsho Shinkeigaku; 2003 Jul; 43(7):385-91. PubMed ID: 14582363
[TBL] [Abstract][Full Text] [Related]
6. Classifying Patients with Amyotrophic Lateral Sclerosis by Changes in FVC. A Group-based Trajectory Analysis.
Ackrivo J; Hansen-Flaschen J; Jones BL; Wileyto EP; Schwab RJ; Elman L; Kawut SM
Am J Respir Crit Care Med; 2019 Dec; 200(12):1513-1521. PubMed ID: 31322417
[No Abstract] [Full Text] [Related]
7. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis.
Rooney J; Burke T; Vajda A; Heverin M; Hardiman O
J Neurol Neurosurg Psychiatry; 2017 May; 88(5):381-385. PubMed ID: 27888187
[TBL] [Abstract][Full Text] [Related]
8. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X
Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245
[TBL] [Abstract][Full Text] [Related]
9. A retrospective investigation of the relationship between baseline covariates and rate of ALSFRS-R decline in ALS clinical trials.
Daghlas I; Lever TE; Leary E
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):206-211. PubMed ID: 29260911
[TBL] [Abstract][Full Text] [Related]
10. [Revised amyotrophic lateral sclerosis functional rating scale at time of diagnosis predicts survival time in amyotrophic lateral sclerosis].
Liu XX; Fan DS; Zhang J; Zhang S; Zheng JY
Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(35):2472-5. PubMed ID: 20137433
[TBL] [Abstract][Full Text] [Related]
11. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
12. Disease progression in amyotrophic lateral sclerosis: predictors of survival.
Magnus T; Beck M; Giess R; Puls I; Naumann M; Toyka KV
Muscle Nerve; 2002 May; 25(5):709-714. PubMed ID: 11994965
[TBL] [Abstract][Full Text] [Related]
13. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.
Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP
Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653
[TBL] [Abstract][Full Text] [Related]
14. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing?
Czaplinski A; Yen AA; Simpson EP; Appel SH
Arch Neurol; 2006 Aug; 63(8):1139-43. PubMed ID: 16908741
[TBL] [Abstract][Full Text] [Related]
15. Trends of quality of life changes in amyotrophic lateral sclerosis patients.
Shamshiri H; Fatehi F; Abolfazli R; Harirchian MH; Sedighi B; Zamani B; Roudbari A; Razazian N; Khamseh F; Nafissi S
J Neurol Sci; 2016 Sep; 368():35-40. PubMed ID: 27538598
[TBL] [Abstract][Full Text] [Related]
16. UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort.
Vidal-Taboada JM; Lopez-Lopez A; Salvado M; Lorenzo L; Garcia C; Mahy N; Rodríguez MJ; Gamez J
J Neurol; 2015 Oct; 262(10):2285-92. PubMed ID: 26162714
[TBL] [Abstract][Full Text] [Related]
17. [Clinical polymorphism of amyotrophic lateral sclerosis].
Kovrazhkina EA; Razinskaya OD; Gubsky LV
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):4-10. PubMed ID: 28884711
[TBL] [Abstract][Full Text] [Related]
18. Comparison of slow and forced vital capacities on ability to predict survival in ALS.
Pinto S; de Carvalho M
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Nov; 18(7-8):528-533. PubMed ID: 28741375
[TBL] [Abstract][Full Text] [Related]
19. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.
Yokoi D; Atsuta N; Watanabe H; Nakamura R; Hirakawa A; Ito M; Watanabe H; Katsuno M; Izumi Y; Morita M; Taniguchi A; Oda M; Abe K; Mizoguchi K; Kano O; Kuwabara S; Kaji R; Sobue G;
J Neurol; 2016 Jun; 263(6):1129-36. PubMed ID: 27083563
[TBL] [Abstract][Full Text] [Related]
20. Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
Zhang YJ; Fan DS
Chin Med J (Engl); 2016 Jan; 129(1):28-32. PubMed ID: 26712429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
